MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

61 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
2	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	Active, not recruiting	Closed	Durvalumab + Tremelimumab	NCT02815995
1	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	DS-6157a	NCT04276415
2	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	Closed	Dovitinib	NCT01831726
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
1/2	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Terminated	Closed	CB-839 + Talazoparib	NCT03875313
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + GSK1120212	NCT01155453
1	Administration of BIIB028 to Subjects With Solid Tumors	Ongoing, but not recruiting	Closed	BIIB028	NCT00725933
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
1	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BEZ235 + MEK162	NCT01337765
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
1	Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ongoing, but not recruiting	Closed	BAY80-6946 + BAY86-9766	NCT01392521
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045

MD Anderson Cancer Center

61 trials at this site

First | Previous | Page 3 of 4 | Next | Last